ABVC BioPharma, Inc. income statement ABVC

Annual Quarterly

It recorded a net loss of $736,934. Diluted earnings per share were -$0.03.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the same quarter a year earlier.

Line	Q2 FY2026 Jun 30, 2026	Q1 FY2026 Mar 31, 2026	Q4 FY2025 Dec 31, 2025	Q3 FY2025 Sep 30, 2025	Q2 FY2025 Jun 30, 2025	Q1 FY2025 Mar 31, 2025	Q4 FY2024 Dec 31, 2024	Q3 FY2024 Sep 30, 2024
Revenue	—	—	-0	1	—	—	0 -9.2%	0 +2350.7%
Cost of revenue	—	—	—	—	—	—	0 -100.0%	0 -99.0%
Gross profit	—	—	—	—	—	—	0 +101.4%	0 +2933.1%
Research and development	0 -31.8%	0 +14.7%	0 -9.1%	0 -21.0%	0 -17.6%	0 -58.2%	0 -55.7%	0 -73.2%
Selling, general and administrative	1 -27.0%	1 +22.2%	1 +151.6%	1 +43.2%	1 +5.6%	1 -16.7%	0 -79.6%	1 -52.8%
Operating income	-1 +66.0%	-2 -126.9%	-2 -212.1%	-2 -549.8%	-2 -166.8%	-1 +75.6%	-1 -37.7%	-0 +86.0%
Interest income	0 -96.4%	0 -80.3%	0 +585.4%	0 +6.8%	0 -29.5%	0	0	0
Foreign currency gain (loss)	0 -91.6%	-0 -416.1%	-0 -77.4%	-0 -469.9%	0 +309.9%	-0 -116.3%	-0 -165.7%	0 +221.4%
Gain (loss) on investments	-0 +44.9%	-0 +38.3%	—	—	-0	-0	-0	-0
Other non-operating income (expense)	0 +195.6%	-0 -185.4%	-0 -111.4%	0 +130.7%	-0 -121.6%	0 -92.3%	0 +1850.4%	-0 +33.7%
Equity in earnings of affiliates	-0 +44.9%	-0 +38.3%	-1	-0 +20.1%	-0 +43.2%	-0	—	-0
Pretax income	-1 +64.9%	-2 -79.0%	-3 -278.7%	-2 -327.6%	-2 -99.4%	-1 +67.7%	-1 -51.7%	-0 +85.5%
Income tax	—	—	0	0 +48.5%	0 +121.3%	—	0 -100.0%	0 +135.5%
Net income	-1 +67.3%	-2 -85.3%	-3 -278.2%	-2 -417.4%	-2	-1 +70.3%	-1 -90.8%	-0 +88.1%
Basic EPS	-0.03 +76.9%	-0.06 +0.0%	-0.11 -114.2%	-0.09 -200.0%	-0.13 -62.5%	-0.06 +79.3%	0.79 +1465.4%	-0.03 +96.3%
Diluted EPS	-0.03 +76.9%	-0.06 +0.0%	-0.11 -114.2%	-0.09 -200.0%	-0.13 -62.5%	-0.06 +79.3%	0.79 +1465.4%	-0.03 +96.3%
Weighted average shares, basic	26 +49.9%	25 +70.0%	25 +87.1%	23 +87.5%	17 +53.6%	15 +53.7%	13 +98.5%	12 +205.9%
Weighted average shares, diluted	26 +49.9%	25 +70.0%	25 +87.1%	23 +87.5%	17 +53.6%	15 +53.7%	13 +98.5%	12 +205.9%
Other measures
Depreciation and amortization	0 -10.3%	0 -17.6%	0 -44.4%	0 -17.0%	0 +3.1%	0 +446.0%	0 +37.4%	0 -6.0%
EBITDA	-1 +66.4%	-2 -128.4%	-2 -215.9%	-2 -563.2%	-2 -169.4%	-1 +75.8%	-1 -37.7%	-0 +86.2%
Interest coverage	-18.42x	-31.85x	-67.55x	-63.45x	-17.73x	-3.11x	-3.25x	-1.37x
Margins
Gross margin	—	—	—	—	—	—	100.00%	99.92%
Operating margin	—	—	439.83%	-246.79%	—	—	-35,837.44%	-77.66%
Pretax margin	—	—	603.35%	-261.69%	—	—	-40,515.11%	-125.12%
Profit margin	—	—	553.45%	-256.61%	—	—	-37,211.29%	-101.41%
EBITDA margin	—	—	438.67%	-246.06%	—	—	-35,307.43%	-75.86%

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: ABVC (Nasdaq), ECOC (OTC)
Fiscal year ends: December 31
Incorporated in: NV
Headquarters: Fremont, CA
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1173313
Former names: American BriVision (Holding) Corp (until Apr 8, 2021); METU BRANDS, INC. (until Jan 8, 2016); Ecology Coatings, Inc. (until Sep 2, 2015); ECOLOGY COATINGS, INC. (until Sep 2, 2015); OCIS CORP (until Jun 13, 2007)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.